Prenetics Global (NASDAQ:PRE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Prenetics Global (NASDAQ:PRE) from a hold rating to a buy rating in a research note issued to investors on Saturday.

A number of other equities analysts also recently commented on PRE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Wednesday, October 8th. Cantor Fitzgerald raised their price target on shares of Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $32.00.

Prenetics Global Stock Performance

Shares of PRE opened at $11.79 on Friday. Prenetics Global has a fifty-two week low of $3.09 and a fifty-two week high of $17.99. The business’s 50-day moving average is $13.25 and its two-hundred day moving average is $9.75. The company has a market capitalization of $198.43 million, a P/E ratio of -4.79 and a beta of 0.35.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.14. Prenetics Global had a negative return on equity of 30.12% and a negative net margin of 60.70%.The business had revenue of $23.56 million during the quarter, compared to analysts’ expectations of $26.00 million. Prenetics Global has set its FY 2025 guidance at EPS. Analysts forecast that Prenetics Global will post -3.3 EPS for the current year.

Institutional Investors Weigh In On Prenetics Global

A number of institutional investors have recently made changes to their positions in PRE. JPMorgan Chase & Co. acquired a new position in shares of Prenetics Global in the 3rd quarter worth approximately $65,000. Nomura Holdings Inc. raised its position in Prenetics Global by 3.3% in the first quarter. Nomura Holdings Inc. now owns 333,528 shares of the company’s stock valued at $1,307,000 after purchasing an additional 10,576 shares during the period. Stevens Capital Partners acquired a new position in Prenetics Global during the second quarter worth $137,000. UBS Group AG lifted its stake in Prenetics Global by 581.9% during the third quarter. UBS Group AG now owns 46,561 shares of the company’s stock worth $619,000 after purchasing an additional 39,733 shares in the last quarter. Finally, Aberdeen Group plc purchased a new position in shares of Prenetics Global during the third quarter worth $979,000. 25.01% of the stock is currently owned by institutional investors and hedge funds.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.